Biochemistry and Molecular Biology of Mechanisms of Action of Fibrates – An Overview

Main Article Content

A.S. V. Prasad

Abstract

Fibrates are a class of medication that mainly lowers the blood triglyceride levels. They reduce the LDL and increase the levels of HDL C, in the blood. Clofibrate, the first member to be discovered  in 1962 , and introduced in USA in 1967, is withdrawn in 2002, due to unexplained hepatomegaly, hepato-toxicity and possible risk of hepatic cancer. Other fibrates are introduced in the late 1970s and early 1980s, such as gemfibrozil in the United States and bezafibrate and ciprofibrate in Europe. Their lipid lowering effects are found to decrease CVS risk , progression of atherosclerosis and metabolic syndrome,  macrovascular and microvascular diabetic complications  like stroke, myocardial infarction, peripheral vascular disease  and  diabetic  retinopathy .Various clinical trials like VA-HIT trial (Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial) ,  FIELD trail.  (the Fenofibrate Intervention and Event Lowering in Diabetes) Helsinki Heart Study,   ACCORD -Lipid trial  (The lipid component of the Action to Control Cardiovascular Risk in Diabetes trial ) and  BIP (Bezafibrate Infarction Prevention Study)  trial and angiography trials, like LOCAT (Lopid Coronary Angiography Trial)  and BECLAIT (Bezafibrate Coronary Atherosclerosis Intervention Trial) demonstrated the  beneficial effects of gemfibrozil and fenofibrate. 
Their mechanism of action remained obscure for three decades, ie till 1990s, when their mode of action was found. The Mechanism of action of fibrates include limitation of substrate availability for triglyceride synthesis in the liver, promotion of the action of lipoprotein lipase, (LPL)
 modulation of low density lipoprotein receptor/ligand interaction and stimulation of reverse cholesterol transport The biochemical and molecular mechanisms involving  the various  enzymes like LCAT (Lecithin-cholesterol acyl transferase)  and CYP7A1 etc.  (cholesterol 7-alpha-monooxygenase or cytochrome P450 7A1 (CYP7A1) ) ,  transporters like ABC , CETP (ATP-binding cassette transporter, Cholesterol ester binding protein) and NTCP, OATP (Na+-dependent taurocholate transporter / organic anion transporters) . These are the.) and nuclear factors like LXR, PPAR alfa etc. (liver orphan receptor α , and peroxisome proliferative nuclear factor) , in relation to the mechanisms  of action of fibrates are discussed . Areas of current interests in literature are briefed.

Keywords:
Fenofibrate, gemfibrozil, reverse cholesterol transport, CETP, PPARs, CYP7A 1, LCAT, NTCP, OATP.

Article Details

How to Cite
Prasad, A. (2019). Biochemistry and Molecular Biology of Mechanisms of Action of Fibrates – An Overview. International Journal of Biochemistry Research & Review, 26(2), 1-12. https://doi.org/10.9734/ijbcrr/2019/v26i230094
Section
Opinion Article

References

Commission on Biochemical Nomenclature (CBN). Retrieved 2007-03-08.^ Nelson DL; Cox MM; 2000.

Lehninger, Principles of Biochemistry (3rd ed.). New York: Worth Publishing.
[ISBN 1-57259]

Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB. VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. JAMA. 2001;285:1585-1591.
DOI: 10.1001/jama.285.12.1585

Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493–498.
DOI: 10.2337/dc08-1543.

Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation. 1992 ;85:37–45.
DOI: 10.1161/01.CIR.85.1.37

Dr. Anthony A. Bavry. Bezafibrate Infarction Prevention Study – BIP American Collage of Cardiology; 2009.

Study Frick MH, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study. Circulation; 1997.

Ericsson CG. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. Eur Heart J; 1998.

Rousse R, Chaignot C, Weill A, Travert F, Hansel B, Marre M, et al. Use of fibrates monotherapy in people with diabetes and high cardiovascular risk in primary care: A french nationwide cohort study based on National Administrative Databases. PLoS ONE. 2015;10(9):e0137733.
DOI:10.1371/journal.pone.0137733

Management of dyslipidaemias with fibrates, alone and in combination with statins: Elsavet , Moutzouri , Anastazia, Keith and Haralampos J, et al. Vasc Health Risk Manag; 2010.

Marshall B Elam, Henry N Ginsberg, Laura C. Lavato, Marshal Corson, et al. Association of fibrates therapy with long term cardiovascular risk in statin treated patients. JAMA Cardiology. 2017;2(4).

Alexander Tenenhaum and Enrique: Fibrates are an essential part of anti-dyslipidemic arsenal: Spotlight on atherogenic dyslipidaemia and residual risk cardiovasc diabetol. 2012;11:125.

Christopher Li Morgan, David R. Owens, primary prevention of diabetic retinopathy with fibrates: A retrospective matched cohort study study published in BMJ open; 2013.

Kate E Shipman, Richard C Strange and Sudarshan Ramachandran. Use of fibrates in the metabolic syndrome: A review. World J Diabetes. 2016;7(5):74–88.7.

Bonovas S, Nikolopoulos GK, Bagos PG. Use of fibrates and cancer risk:

A systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials. Review Article. PLoS One; 2012.

Xin Lian, Gang Wang, Honglan Zhou Show all 6 authors. Anticancer properties of fenofibrate: A repurposing use. Journal of Cancer. 2018;9(9):1527-1537.

Bonovas S, Nikolopoulos GK, Bagos PG. Use of fibrates and cancer risk: A systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials. PLoS ONE. 2012;7(9):e45259.
DOI:10.1371/journal

Wu J, et al. Rhabdomyolysis associated with fibrate therapy: Review of 76 published cases and a new case report. Review Eur J Clin Pharmacol; 2009.

Kajuya Kato, Astushi Nagase, Iand Hiroyuki Furuk. Rabdomyolysis associated with fenofibrate associated monotherapy in a patient with chronic myelogenous leukemia case rep gastroenterol. 2011;5(2):492-496.

Dawei Wang, Yanqiu Wang. Fenofibrate monotherapy-inducedi rhabdomyolysis in a patient with hypothyroidism. A rare case report and literature review Medicine (Baltimore); 2018.

Rifkind BM. Effect of CPIB ester on plasma free fatty acid levels in man. Metab (Clin. Exp.). 1966;25:673-675.

Greenberg AS, Shen WJ, Muliro K, Patel S, Souza SC, Roth RA, Kraemer FB. Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway. J. Biol. Chem. 2001;276:45456–45461.

Cook KG, Yeaman SJ, Stralfors P, Fredrikson G, Belfrage P. Direct evidence that cholesteryl ester hydrolase from adrenal cortex is the same enzyme as hormone-sensitive lipase from adipose tissue. Eur. J. Biochem. 1982;125:245–249.22.

Lee FT, Adams JB, Garton AJ, Yeaman SJ. Hormone-sensitive lipase is involved in the hydrolysis of lipoidal derivatives of estrogens and other steroid hormones. Biochim. Biophys. Acta. 1988;963:258–2.

Wei S, Lai K, Patel S, Piantedosi R, Shen H, Colantuoni V, Kraemer FB, Blaner WS. Retinyl ester hydrolysis and retinol efflux from BFC-1β adipocytes. J. Biol. Chem. 1997;272:14159–14165.

Cedric Moro, et al. Natriuretic peptides and cGMP signaling control of energy homeostasis. Am J Physiol Heart Circ; 2013.

Hartman JJ, Mahr J, McNally K, Okawa K, Iwamatsu A, Thomas S, Cheesman S, Heuser J, Vale RD, McNally FJ. Katanin, a microtubule-severing protein, is a novel AAA ATPase that targets to the centrosome using a WD40-containing subunit. Cell. 1998;93:277–287.

SM Grundy, EH Ahrens Jr, G Salen, Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. Journal of Lipid Research. 1972;13(4):531–551.

Leiss K. von Bergmann, Gnasso A, Augustin J, Effect of gemfibrozil on biliary metabolism in normolipemic subjects. Metabolismml: Clinical and Experimental. 1985;34(1):74–82.

LR Brunham, Singaraja RR, Hayden MR, Variations on a gene: Rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annual Review of Nutrition. 2006;26:105–129. View at Google Scholar.

McNeish, Aiello RJ, Guyot D, et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATp-binding cassette transporter-1. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(8):4245–4250.

van der Hoogt CC, De Haan W, Westerterp M, et al.. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. Journal of Lipid Research. 2007;48(8):1763–1771.

Akiyama TE, Sakai S, Lambert G, et al. Conditional disruption of the peroxisome proliferator-activated receptor? gene in mice results in lowered expression of ABCA1, ABCG1 and apoe in macrophages and reduced cholesterol efflux. Molecular and Cellular Biology. 2002;22(8):2607–2619.

Venkateswaran A, Laffitte BA, Joseph SB, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRa. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(22):12097–12102.

A Chawla, Boisvert WA, Lee CH, et al. A PPAR?-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Molecular Cell. 2001;7(1):161–171.

BA Laffitte, Joseph SB, Walczaketal R. Autoregulation of the human liver X receptor apromoter. Molecular and Cellular Biology. 2001;21(22):7558–7568.

DD Patel, Knight BL, Soutar AK, Gibbons GF, Wade DP. The effect of peroxisome-proliferator-activated receptor-α on the activity of the cholesterol 7α-hydroxylase gene. Biochemical Journal. 2000;351(3):747–753.

SM Post, Duez H, Gervois PP, Staels B, Kuipers F, Princen HMG. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-α-mediated downregulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase expression. Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21(11):1840–1845.

Diczfalusy U, Lund E, Lütjohann D, Björkhem I. Novel pathways for elimination of cholesterol by extra hepatic formation of side-chain oxidized oxysterols. Scandinavian Journal of Clinical and Laboratory Investigation, Supplement. 1996;56(226):9–17.

Bjorkhem I, Diczfalusy U, Lutjohann D. Removal of cholesterol from extrahepatic sources by oxidative mechanisms. Current Opinion in Lipidology. 1999;10(2):161–165.

Szanto A, Benko S, Szatmari I, et al. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor and liver X receptor signaling in macrophages,” Molecular and Cellular Biology. 2004;24(18):8154–8166.

Quinn CM, Jessup W, Wong J, Kritharides L, Brown AJ. Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: A role for RXR and PPARγ ligands. Biochemical Journal. 2005;385(3):823–830.

Duez H SM, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated down regulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol. 2001;21:1840.

Kok T, Bloks VW, Wolters H, et al. Peroxisome proliferator-activated receptor a (PPARa)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochemical Journal. 2003;369(3);539–547.

Landrier JF, Thomas C, Grober J, et al. The gene encoding the human ileal bile acid-binding protein (I-BABP) is regulated by peroxisome proliferator-activated receptors. Biochimica et Biophysica Acta, 2005;1735(1):41–49.

JP Després. Increasing high-density lipoprotein cholesterol: An update on fenofibrate. American Journal of Cardiology. 2001;88(12A):30N–36N.

Vu-Dac N, Chopin-Delannoy S, Gervois P, et al. The nuclear receptors peroxisome proliferator-activated receptor a and rev-erba mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. Journal of Biological Chemistry. 1998;273(40):25713–25720.

Shen Qu, Dongming Su, Jennifer Altomonte, Adama Kamagate, Jing He, German Perdomo, Tonia Tse, Yu Jiang, H Henry Dong. PPARα mediates the hypolipidemic action of fibrates by antagonizing FoxO1. American Journal of Physiology-Endocrinology and Metabolism. 2007;292(2):E421-E434.